Questions and responses 41st Parliament, 1st session June 2, 2011, to September 13, 2013

Refine your search

Search results for topic:"Canadian Institutes of Health Research"

Results 1-6 of 6

Results from historical information do not include searching within the departmental responses.
Historical information
The information shown below relates to a prior session.

Q-855

41-1
June 2, 2011, to September 13, 2013

Q-855

41st Parliament, 1st session
Asked by
Date asked
September 13, 2012
Answered
October 31, 2012
With regard to the impact that the cuts announced in Budget 2012 will have on the Canadian Institutes of Health Research: (a) where will the increases or decreases occur in relation to the forecast amounts in place before the budget was tabled on March 29, 2012, broken down by institute; (b) for each institute in point (a), (i) what are the amounts of the planned increases or decreases in human resources and funding, (ii) will positions be eliminated and, if so, how many; (c) which initiatives, institutes or programs will be eliminated by Budget 2012; (d) what are the reductions in transfer payments to the provinces or territories and municipalities, broken down by (i) initiative, (ii) province or territory; and (e) which grant or contribution agreements will be reduced or cancelled, broken down by (i) program or initiative, (ii) recipient?
Historical information
The information shown below relates to a prior session.

Q-10

41-1
June 2, 2011, to September 13, 2013

Q-10

41st Parliament, 1st session
Asked by
Date asked
June 6, 2011
Answered
September 19, 2011
With respect to the full process currently being undertaken by the Canadian Institutes of Health Research (CIHR) regarding chronic cerebrospinal venous insufficiency (CCSVI), including the August 26, 2010, meeting of the Scientific Expert Working Group (SEWG) and the CIHR’s “knowledge synthesis review”: (a) what is the accepted operating definition of “conflict of interest” for the CIHR, (i) why was no disclosure statement made by all participants who attended the August 26, 2010, joint meeting of the CIHR and the Multiple Sclerosis Society of Canada (MSSC), (ii) are there plans to provide an opportunity to declare possible conflicts of interest subsequent to the meeting; (b) what are the details of all information produced and circulated by the CIHR in January 2011 regarding follow-up care for multiple sclerosis (MS) patients and to which organizations was the information sent; (c) will the disclosure statement to be signed by members of the SEWG at its next meeting in June 2011 include specific reference to any (i) consultancy, (ii) grant support, (iii) membership on advisory councils, (iv) speaker’s bureau, (v) other sources of funding a member might have; (d) how does the CIHR plan to ensure that all members of the SEWG have the same understanding of private or personal interests that could influence decision-making; (e) will all disclosure statements in (c) be made publicly available and, if so, when, and, if not, why not; (f) which, if any, of the SEWG’s members have been trained in Dr. Zamboni’s methods and by whom were these members trained; (g) which, if any, of the SEWG’s members have watched diagnosis and treatment of CCSVI and, for each member identified (i) where did this observation take place, (ii) under what guidance, (iii) how many images and treatments were studied by the member; (h) which, if any, of the SEWG’s members have undertaken diagnosis and treatment of CCSVI and, for each member identified, (i) where were these actions performed, (ii) under what guidance, (iii) how many images and treatments were performed by the member; (i) does the CIHR recognize the emerging scientific discipline of neurovascular disease; (j) does the SEWG include any members of the International Society for NeuroVascular Disease (ISNVD) and, if so, who are these members, and, if not, why not; (k) which, if any, members of the SEWG have attended any of the ISNVD’s conferences, specifying for each such member the conferences that he or she attended; (l) does the inclusion of investigators of the seven MS Society-funded studies in the SEWG comply with the CIHR’s operating definition of “conflict of interest” and, if so, what are the reasons that explain this compliance; (m) regarding the “knowledge synthesis review”, (i) what is the protocol for the review, (ii) how is research deemed to be, or not to be, pertinent, (iii) who specifically is undertaking the review, how were they chosen, and what expertise do they have to undertake the review, (iv) why has the CIHR decided to have them undertake the review, (v) what are the CIHR’s reasons for not having the SEWG undertake the review, (vi) what is the cost of the review, (vii) what is a comprehensive list of abstracts to be reviewed, (viii) what additional material, people, or other sources will be consulted, (ix) will the review include scientific evidence presented at all the major scientific conferences on CCSVI to date, namely, Hamilton (February 2010), New York (July 2010), Washington (October 2010), Katowice (March 2011), Bologna (March 2011), Chicago (April 2011), and San Diego (May 2011), (x) will the review include contacting the leading experts in the field, asking for their unpublished data, visiting their laboratories and operating theatres, (xi) if the answer to (m)(x) is in the affirmative, what, if any, protocol has been established for each contact, and what, if any, weighting will be applied to this evidence; (n) how does the CIHR plan to weigh or asses the seven MS Society-funded studies and the “knowledge synthesis review” in its establishment of any future policy, particularly in its deliberations on whether to undertake clinical trials for CCSVI in Canada; (o) which , if any, members of the SEWG have attended any CCSVI conferences, specifying for each such member (i) what conferences he or she attended, (ii) in what capacity, (iii) who paid for the trip or attendance at the conference, (iv) what written evidence did he or she report to either the CIHR or SEWG, (v) if no written evidence was reported, why not; (p) which members of the CIHR have attended any CCSVI conferences, specifying for each such member (i) what conferences he or she attended, (ii) in what capacity, (iii) who paid for the trip or attendance at the conference, (iv) what written evidence he/she reported to either the CIHR or SEWG, (v) if no written evidence was reported, why not; (q) why has the CIHR decided not to further investigate CCSVI through clinical trials; (r) why has the CIHR decided not to follow recommendations made by the Ontario Association of Neurologists, the Canadian Society of Radiologists, the Canadian Society of Vascular Surgery, the American Society of Interventional Radiology, and the International Union of Phlebology regarding CCSVI; (s) what does the CIHR consider an “appropriate pace”, a term used in its May 18, 2011, e-mail to Dr. Kirsty Duncan, Member of Parliament for Etobicoke North, for the introduction to Canada of any potential new medical treatment for any medical condition, and how much evidence does the CIHR consider is required before a treatment should undergo clinical trials in Canada in terms of (i) the number of procedures undertaken, (ii) the number of countries undertaking the procedure, (iii) scientific evidence presented in academic peer-reviewed journals, (iv) scientific evidence presented at academic conferences, (v) scientific evidence presented at academic conferences for conditions that are progressive diseases, especially progressive diseases for which there are limited or no options for treatment; (t) what is the CIHR’s accepted protocol, including all necessary steps, for bringing a new treatment to clinical trials in Canada, (i) when was the protocol established, (ii) what treatments have undergone clinical trials as a result of the protocol, (iii) which treatments have been rejected to date; (u) is the creation of a SEWG a standard step in the CIHR’s protocol for bringing a new treatment to clinical trials in Canada, and, (i) if so, since the creation of the protocol, what are all new treatments and their associated SEWGs, (ii) if not, why was this step deemed necessary for approval of clinical trials for CCSVI; (v) what are the last five medical treatments for any medical condition accepted by the CIHR for use in Canada and, for each treatment, what are the details of all evidence required by the CIHR in its decision to have the treatment undergo clinical trials, including, but not limited to, the number of procedures undertaken, the countries undertaking the procedure, and scientific evidence presented in both peer-reviewed journals and academic conferences; and (w) with regard to the MS registry announced March 23, 2011, (i) who specifically is collecting the information, (ii) what precise information is being collected, (iii) what consent will be necessary from patients for any data collection, (iv) when will information begin to be collected, (v) what specific information is being collected regarding the treatment of CCSVI, (vi) what information is being gathered or tracking is being done of individuals who have chosen to have the liberation procedure outside Canada?
Historical information
The information shown below relates to a prior session.

Q-264

41-1
June 2, 2011, to September 13, 2013

Q-264

41st Parliament, 1st session
Asked by
Date asked
November 30, 2011
Answered
January 30, 2012
With respect to the planning for and the execution of the joint meeting of the Canadian Institutes for Health Research (CIHR) and the Multiple Sclerosis Society of Canada (MSSC), on August 26, 2010: (a) what were the most recent statistics CIHR had regarding MS as of August 26, 2010, and had CIHR received, internally or externally, any request to update the figures beforehand; (b) what criteria were used to identify which international experts in chronic cerebrospinal venous insufficiency (CCSVI) should be invited to the August 26, 2010, meeting, and, (i) was Dr. Mark Haacke a candidate for invitation and, if so, why was he not invited, (ii) was Dr. Marion Simka a candidate for invitation and, if so, why was he not invited, (iii) was Dr. Paolo Zamboni a candidate for invitation, and, if so, why was he not invited, (iv) which invitees had expertise or experience administering CCSVI treatment, (v) why did the criteria not exclude from participation individuals who had publicly criticized the validity of CCSVI, (vi) what was the rationale for “[keeping] the international participation in focus” (Answer to Access to Information Request ATI 2010-006); (c) what CIHR experts were consulted regarding CCSVI/MS prior to the August 26, 2010, meeting, and, if any CIHR experts were consulted, what recommendations did they make, including any recommendations concerning large multi-centre clinical trials; (d) what briefings did the Minister of Health provide to members of the Conservative caucus regarding CCSVI or MS prior to the August 26, 2010, meeting, (i) what were the dates of any briefings, (ii) what information was provided; (e) did provincial governments express “mounting pressure” (ATI 2010-006) from the public regarding the need for clinical trials and treatment for CCSVI, and, if so, which provinces expressed any such pressure; (f) did any of the provinces and territories communicate an interest in partnering with the federal government on a “potential initiative” (ATI 2010-006), and, if so, what were the details of the “potential initiative” (ATI 2010-006); (g) by what date and by whom was CIHR made aware of the history of the theory of abnormal vasculature in MS dating back more than 100 years; (h) what was CIHR’s rationale for focussing its literature review on CCSVI and for excluding from consideration literature on the theory of abnormal vasculature in MS and why did CIHR decide to have students work on this literature review; (i) what criteria did the CIHR use to determine which of the 19 studies identified through PubMed (July 2010) it would include in its review of existing literature and research; (j) on what date did the President of CIHR first state that he would be pleased to provide for a randomized control trial on CCSVI treatment for review at the next grant competition, and (i) did the President ever speak to the “F/P/T” (ATI 2010-006) regarding the need for randomized clinical trials; (k) what lobbyists and/or pharmaceutical companies asked for a meeting with the Minister of Health’s office prior to August 26, 2010, to discuss a new oral MS drug and CCSVI treatment, and (i) what lobbyists and/or companies were “well respected” (ATI 2010-006) and had “a solid reputation with the MSSC” (ATI 2010-006); (l) why did CIHR change its position in March 2011 regarding an MS registry, and how was this change possible, given CIHR’s previous statements to Dr. Carolyn Bennett and Dr. Kirsty Duncan that the creation of such a registry “was outside” their “mandate” (ATI 2010-006); (m) did CIHR have money available for funding clinical trials related to CCSVI, (i) was CIHR “overcommitted” (ATI 2010-006), (ii) if so, by how much, (iii) could CIHR have found “some money” (ATI 2010-006), (iv) when could money have been available; (n) prior to the August 26, 2010, meeting, how many provinces and territories “expressed some level of support for a clinical trial” (ATI 2010-006); (o) concerning the e-mail exchange of August 24, 2011, contained in the response to ATI 2010-006, did the Minister of Health "have authority or [did] she need to go through cabinet" (ATI 2010-006); (p) were abnormal veins discussed in any of the August 26, 2010, presentations, and, if so, (i) which presenters covered this issue, (ii) what historical papers were referenced; (q) was iron accumulation in MS brains discussed in any of the August 26, 2010, presentations, and, if so, (i) which presenters covered the issue, (ii) what historical papers were referenced; (r) did any of the presentations explore a possible relationship between abnormal brain veins and tissue damage in MS, and, if so, (i) which presenters covered the issue, (ii) what historical papers were referenced; (s) what criteria were used or what process was followed to prepare the Summary Report of the August 26, 2010, meeting and, specifically, why was no reference made in the Summary Report to historical papers discussing abnormal vasculature and iron accumulation; and (t) does the Summary Report of the August 26, 2010, meeting disclose potential conflicts of interests of the attendees, and, if not, why was this information not included?
Historical information
The information shown below relates to a prior session.

Q-874

41-1
June 2, 2011, to September 13, 2013

Q-874

41st Parliament, 1st session
Asked by
Date asked
September 17, 2012
Answered
November 1, 2012
With regard to the Canadian Institutes of Health Research’s Scientific Expert Working Group: (a) was the Scientific Expert Working Group aware that on December 7th, 2010, Dr. Beaudet assured the Subcommittee on Neurological Disease that “no physician will refuse to see and treat them for complications of a treatment received abroad”; (b) why did the Scientific Expert Working Group state that “media reports that have stated that Multiple Sclerosis (MS) patients who experience complications after Chronic Cerebrospinal Venous Insufficiency (CCSVI) treatment are not being seen by Canadian doctors are not justified”, (i) what patients or patient advocacy groups were interviewed, (ii) what evidence was reviewed, (iii) what action was taken; (c) which of the provincial guidelines for follow up care does the Scientific Expert Working Group support; (d) what was the action undertaken by the government to ensure that all patients receive follow-up care, including patients suffering from complications from CCSVI treatments received abroad; (e) when was the Sub-Committee of the Scientific Expert Working Group formed, (i) why was it formed, (ii) who are the members of the sub-committee, (iii) what prompted a meeting to develop criteria for a recommendation for clinical trials on June 13th, 2011; (f) why did the Scientific Expert Working Group fail to sign a declaration of conflict of interest until June 2011; (g) what specific results were available from the seven MS Society of Canada-funded studies on June 28th 2011; (h) with respect to the Scientific Expert Working Group’s consensus workshop on ultrasound imaging, (i) on what date did the meeting take place, (ii) who was in attendance, (iii) what were the agenda items, (iv) what were the key recommendations, (v) why was Dr. Sandy McDonald not included, (vi) on what items did the group come to consensus; (i) what is the budget for the Scientific Expert Working Group specifically, (i) the monies allotted for 2010-2011, (ii) 2011-2012, (iii) the monies allocated for travel, (iv) the monies allocated for accommodation, (v) why was Agreement no 1148 to be signed at the end of February 2011 for monies that were to be available for 2010-2011; (j) with respect to Agreement no 1148 to support the Scientific Expert Working Group between the CIHR and the MS Society of Canada, (i) was the agreement ever signed and, if so (i) on what date, (ii) who made the grant application for the President’s Fund and on what date, (iii) what was the grant specifically for, (iv) why is the MS Society of Canada responsible for planning, support and implementation of the Scientific Expert Working Group, (v) what action is being taken to ensure that there are no conflicts of interest; (k) how many researchers/research groups applied for the Phase 1/11 clinical trial, and from what institutions; and (l) what has caused the delay in announcing the research team which was to be named by mid-April 2012?
Historical information
The information shown below relates to a prior session.

Q-1254

41-1
June 2, 2011, to September 13, 2013

Q-1254

41st Parliament, 1st session
Asked by
Date asked
March 21, 2013
Answered
May 8, 2013
With regard to access to information requests ATI 2012-005 and 2012-006 submitted by Ms. Kirsty Duncan, M.P., for which a response was sent on February 22, 2013: (a) on what date were the two submissions made and what was the timeframe for completing the response; (b) why were the two requests returned together, some parts featuring page numbers and others not; (c) how many updates have been received from the Canadian Chronic Cerebrospinal Venous Insufficiency (CCSVI) Systematic Review Group to date, (i) how many studies in total have met the criteria for inclusion in the review, (ii) why does the group not identify, for each complication, the number of cases per number of people treated, (iii) why does the government not provide, for each serious complication listed, the number of cases per population treated; (d) on what date was the request for proposals for the CCSVI trials first drafted, (i) how may drafts were undertaken and on what dates, (ii) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (iii) on what date did the provincial and territorial Ministers of Health review the draft, (iv) what was the feedback provided; (e) why, on November 22, 2012, was the amount available for the CCSVI trials in the range of $3-5 million, (i) what is the significance of the expression "should we just fudge a number"; (f) how was the decision made to earmark $3 million for the CCSVI trials and on what date was the decision made; (g) on what date and at what time was the Request for Applications (RFA) announcement for clinical trials published on the Canadian Institute for Health Research (CIHR)'s website, (i) on what date and at what time was Bill C-280, An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI), scheduled to be debated; (h) why was there a change by the President's office at CIHR that the commitment from the CIHR be $2 million with the balance to come from partners, i.e. the Multiple Sclerosis Society of Canada (MSSC) and ''relevant provinces and territories'', and what were the relevant provinces and territories referred to; (i) how many versions of the Multiple Sclerosis (MS) research update deck were produced and on what dates, (i) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (ii) when was the final draft presented, and for what purpose; (j) how many government MPs has the Health Minister met with on the issue of CCSVI/MS since May 2010, and how many government MPs have the Minister's officials met with on the issue of CCSVI/MS since May 2010; (k) how many draft speeches were prepared for government MPs for Motion M-274, (i) how many versions of each speech were produced and on what dates, (ii) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (iii) how many government MPs read these prepared speeches; (l) regarding the briefing note for Dr. Alain Beaudet`s meeting with Dr. Jeffrey Turnbull, President of the Canadian Medical Association (CMA) on December 21, 2010, why did a recommendation in the briefing note state "The possibility of the CMA producing a position statement regarding patient access to physicians for patients who have received the Zamboni procedure", and "The fact that CIHR would be willing to provide the CMA with any necessary support in order to produce this statement", when the Scientific Expert Working Group (SEWG) stated that, "media reports that have stated that Multiple Sclerosis (MS) patients who experience complications after Chronic Cerebrospinal Venous Insufficiency (CCSVI) treatment are not being seen by Canadian doctors are not justified"; (m) regarding the briefing note for Dr. Alain Beaudet's meeting with Paul Emile Cloutier, CEO of the CMA on January 31, 2012, which shows CMA President Haggie testified before a Senate committee on Dec 2, 2011, and a House committee on October 17, 2011, (i) did President Haggie bring up at either committee meeting CMA's lack of support for either bills C-280 or S-204, (ii) why was President Haggie unaware of the lack of follow-up care for MS patients treated for CCSVI when President Turnbull was made aware, (iii) why was there a hiatus in correspondence with the CMA, (iv) for how long was the hiatus, (v) when did the hiatus end; (n) regarding the MS-Societies' seven funded studies regarding CCSVI, why was there, at the 18-month mark, an inquiry into the training of the teams, (i) which of the teams were trained by Dr. Zamboni and which individual members of each team were trained by Dr. Zamboni, (ii) which of the teams were trained by Dr. Zivadinov and which individual members of each team were trained by Dr. Zivadinov, (iii) which teams were trained by neither or by another team; (o) how many people worked on drafts of prepared speeches for bill C-280, An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI), for how many hours, and at what average cost to taxpayers and how many government MPs read these prepared speeches; (p) how many people worked on drafts of prepared speeches for bill S-204, An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI), for how many hours, and at what average cost to taxpayers, (i) how many government Senators read these prepared speeches; (q) on what dates was the Canadian MS Monitoring System to be ready to receive data and when did the system start collecting data; (r) is the government's position regarding MS patients’ input into the Scientific Expert Working Group (SEWG) in accordance with the statement "CIHR's Scientific Expert Working Group includes researchers with expertise in different disciplines such as neurology, vascular surgery and vascular imaging who are treating MS patients and who will be bringing their patients' concerns to the table" (ATIP); (s) is it still the government's position that "Benoit's motion speaks far more to PHAC's monitoring system than anything we are doing on the trials front" (ATIP); (t) how many draft MS slide decks were prepared for Senatorial Caucus, (i) how many versions of each deck were produced and on what dates, (ii) how many people worked on these drafts, for how many hours, and at what average cost to taxpayers, (iii) who presented the deck to the Senatorial Caucus; (u) is the government's position as per the information sheet provided when Dr. Alain Beaudet wrote to the Colleges of Physicians on February 29, 2012 which says, "MS patients who have received a venous procedure abroad should be reassured that they will be continued to be cared for by their physicians and/or regular MS specialists as any other patients?” or is it that follow-up care is primarily the responsibility of provincial and territorial governments to ensure that no Canadian is denied post-treatment and follow-up care (ATIP) and what role does the federal government have if patients are being denied follow-up care by a province or territory; (v) why did the government ask the Multiple Sclerosis Society of Canada (MSSC) on February 7, 2012 about approved venous angioplasty; (w) is it still the government's position that the MS documentary that aired on the Nature of Things on February 9, 2012, was "balanced and fair"; (x) why does a February 16, 2012 e-mail list MS patients who are also CCSVI advocates; (y) is the government's position regarding imaging for CCSVI in accordance with the International Society for NeuroVascular Disease (ISNVD) venography statement and consensus document and, if not, why not; and (z) does the government know how many Canadians are actually impacted by MS, (i) if so, what is the number, (ii) if not, why not; and (aa) when Dr. Alain Beaudet wrote to the Colleges of Physicians on February 29, 2012, (i) why was the list of 11 recent peer-reviewed publications provided not a comprehensive list, (i) why did the list not specify what were positive and negative studies, and what imaging techniques were used, (ii) for MS patients who are denied follow-up care, what recourse and resources do they have, (iii) what is the position of the Scientific Expert Working Group concerning MS patients who have been denied follow-up care, such as Roxanne Garland?
Historical information
The information shown below relates to a prior session. The government is no longer required to respond to this question.

Q-1406

41-1
June 2, 2011, to September 13, 2013

Q-1406

41st Parliament, 1st session
Asked by
Date asked
June 6, 2013
Awaiting response
N/A
With regard to the Minister of Health’s signed response to Order Paper Question Q-1254: (a) how does the Minister and her government define “transparency”; (b) what does the Minister mean by "this Government has been as transparent as possible with parliamentarians and the public on this issue"; (c ) how does taking 225 days to answer Q-1254 meet the Minister’s definition of transparency, (i) how does taking 225 days meet the statement that Ministers are accountable to Parliament, and that they “must answer all questions pertaining to your (sic) areas of responsibility”, as cited in “Accountable Government: A Guide for Ministers and Ministers of State”, (ii) what criteria were used to ensure transparency; (d) how does answering only sub-questions (a), (q) and (z) of Q-1254 meet (i) the Minister’s definition of transparency used in (a), (ii) the guidelines in “Accountable Government”, (iii) what criteria were used to ensure transparency; (e) how does partially answering sub-questions (b), (c), and (n) meet (i) the Minister’s definition of transparency used in (a), (ii) the guidelines in “Accountable Government”, (iii) what criteria were used to ensure transparency; (f) how does refusing to answer sub-questions (d) to (h), (j), (l) to (m), (r) to (s), (u) to (y), and (aa) meet (i) the Minister’s definition of transparency used in (a), (ii) the guidelines in “Accountable Government”, (iii) what criteria were used to ensure transparency; (g) why does the government not track by hours, cost, number of drafts, and persons who work on speeches, when it tracks projected costs to answer opposition MPs’ Order Paper questions; (h) who does the government consider to be “key partners” regarding chronic cerebrospinal venous insufficiency (CCSVI) procedure; (i) what are the main CCSVI stakeholders across the country, (i) which, if any, does the government consider a “key partner”, (ii) with which, if any, does the “government communicate on a regular basis”; (j) why does the Canadian Multiple Sclerosis (MS) Monitoring System, which “was ready to receive data as of September 2012”, not contain any submitted data, (i) what are the barriers to having submitted data, (ii) what, if anything, can be done to make the system operational and functional, including, but not limited to, increased political will, human resources, financial resources, or improved cooperation with stakeholders; (k) if new Statistics Canada data was published in September 2012 showing that the number of people living with multiple sclerosis in Canada is 93,500, (i) why did John Wright, President and CEO of the Canadian Institute for Health Information use the numbers 55,000 to 75,000 at the October 4th, 2012 hearings on Bill S-204; (l) regarding the September 6, 2011, consensus workshop to determine the best procedures to standardize imaging of veins in the neck and brain, (i) who were the invited experts, (ii) how many imaging procedures for CCSVI had each expert undertaken, (iii) by whom were each of the experts trained, (iv) how many of the experts were funded by the Canadian Institutes for Health Research (CIHR); (m) what was the funding by each of CIHR, the MS Society of Canada, and the provinces of British Columbia, Manitoba, and Quebec for the $6 million CCSVI clinical trial; (n) which of (a), (b), or (c) is the government’s position regarding follow-up care (a) "MS patients who have received a venous procedure abroad should be reassured that they will be continued to be cared for by their physicians and/or regular MS specialists as any other patients?" (ATIP), (b) follow-up care as an issue that is primarily the responsibility of provincial and territorial governments (ATIP) or (c) “the federal government has provided regular MS research updates to provincial and territorial jurisdictions, which have the responsibility to ensure that Canadians receive appropriate health treatments and follow-up care” (answer to Order Paper question Q-1254); (o) what recourse and resources do Canadians who have been treated for CCSVI have should they be denied follow-up care, as Roxanne Garland was; (p) has the government been informed of a preliminary study for CCSVI undertaken in British Columbia, and if so, what were the preliminary results; and (q) has the $6 million CCSVI clinical trial begun and if not, why not, and if so, (i) on what date did patient accrual begin in each of the provinces, (ii) how many patients have been recruited for the trial by province, (iii) how many CCSVI procedures have been undertaken by province?
Top of page